Corporate News

Medicilon Supports Moon Biotech’s Groundbreaking MNO-863 Probiotic Drug – Achieves Nearly 10% Weight Loss in 4 Weeks and Secures Dual Clinical Trial Trial Approvals
Zero Defects! Medicilon Supports MeiJi BioPharma’s Oral Paclitaxel Soft Capsule in Gaining FDA IND Approval
Global First! Medicilon Powers Tyercan’s Breakthrough Anti-Tumor Protein-Drug Tye1001 to U.S. and China IND Clearance
Medicilon Supports Partner Nuoyuan Medical Equipment Co., Ltd. in Securing FDA IND Approval for Class 1 Innovation Drug Pemefolacianine
A Decade of Collaboration: Medicilon Supports SinoRDA in Achieving Approval for Linaprazan Glurate
Medicilon Supports Strategic Partner CGeneTech in Achieving Approval for Next-Generation DPP-4 Inhibitor

Medicilon Academy

Large Animal Models: Essential Tools in Disease Research
PDXO Model: A Significant Advancement in Precision Oncology
Did You Know That Medicilon Can Handle DMPK Studies?
Medicilon’s GLP-1 New Drug R&D Service
Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates
The Role of the Ames Test in Predicting the Genotoxicity of Impurity Compounds in Drugs

Digital Materials

Medicilon DMPK & Bioanalysis Services (Download)
Medicilon—High Quality Integrated Drug R&D Services (Download)
Medicilon Large Animal Pharmacodynamic Research Service Platform (Download)

Search Medicilon

Medicilon Supports Moon Biotech’s Groundbreaking MNO-863 Probiotic Drug – Achieves Nearly 10% Weight Loss in 4 Weeks and Secures Dual Clinical Trial Trial Approvals

Zero Defects! Medicilon Supports MeiJi BioPharma’s Oral Paclitaxel Soft Capsule in Gaining FDA IND Approval

Global First! Medicilon Powers Tyercan’s Breakthrough Anti-Tumor Protein-Drug Tye1001 to U.S. and China IND Clearance

Contact Medicilon

Name
Address